Camizestrant

☆ Save On Wikipedia ↗
Camizestrant
Clinical data
Other namesAZD9833
Routes of
administration		By mouth
Drug classAntineoplastic
ATC code
Identifiers
  • N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC24H28F4N6
Molar mass476.524 g·mol−1
3D model (JSmol)
  • C[C@@H]1CC2=C(C=CC3=C2C=NN3)[C@H](N1CC(F)(F)F)C4=NC=C(C=C4)NC5CN(C5)CCCF
  • InChI=1S/C24H28F4N6/c1-15-9-19-18(4-6-21-20(19)11-30-32-21)23(34(15)14-24(26,27)28)22-5-3-16(10-29-22)31-17-12-33(13-17)8-2-7-25/h3-6,10-11,15,17,23,31H,2,7-9,12-14H2,1H3,(H,30,32)/t15-,23+/m1/s1
  • Key:WDHOIABIERMLGY-CMJOXMDJSA-N

Camizestrant is an experimental medication that is being evaluated for the treatment of breast cancer.[1] It is an estrogen receptor alpha antagonist and a selective estrogen receptor degrader (SERD).[2]

Camizestrant is an oral selective estrogen receptor degrader (ngSERD) and complete estrogen receptor (ER) antagonist.[1] It blocks the activity of estrogen receptor alpha encoded by both wild-type and mutated ESR1 and induces proteasome-dependent degradation of estrogen receptor alpha, without agonizing estrogen receptor alpha.[1]

Society and culture

In May 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Etcamah, intended for the treatment of ER-positive, HER2-negative locally advanced or metastatic breast cancer in people with ESR1 gene mutations.[1] The applicant for this medicinal product is AstraZeneca AB.[1]

The Emirates Drug Establishment of the UAE is the first health agency to approve the drug [3].

Names

Camizestrant is the international nonproprietary name.[4]

References

  1. "Etcamah EPAR". European Medicines Agency (EMA). 22 May 2026. Retrieved 30 May 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. Scott JS, Moss TA, Balazs A, Barlaam B, Breed J, Carbajo RJ, et al. (December 2020). "Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist". Journal of Medicinal Chemistry. 63 (23): 14530–14559. doi:10.1021/acs.jmedchem.0c01163. PMID 32910656.
  3. Saseendran S (11 June 2026). "UAE first country in world to approve new oral breast cancer drug for hormone-resistant cases".
  4. World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87". WHO Drug Information. 36 (1). hdl:10665/352794.